MARKET

BMEA

BMEA

Biomea Fusion, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.20
+0.10
+1.41%
After Hours: 7.20 0 0.00% 16:01 01/24 EST
OPEN
6.88
PREV CLOSE
7.10
HIGH
7.27
LOW
6.61
VOLUME
748.33K
TURNOVER
--
52 WEEK HIGH
22.22
52 WEEK LOW
6.61
MARKET CAP
209.12M
P/E (TTM)
-5.2204
1D
5D
1M
3M
1Y
5Y
Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Simply Wall St. · 01/12 09:24
Biomea Fusion Announces Participation at the H.C. Wainwright 2022 BioConnect Conference
REDWOOD CITY, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible small molecules to treat and improve the live...
GlobeNewswire · 01/11 13:30
BRIEF-Biomea Fusion Announces 2022 Clinical Development Plan
reuters.com · 01/10 13:48
Biomea Fusion Announces 2022 Clinical Development Plan to Initiate Studies in up to Seven Different Tumor Types and in Diabetes for BMF-219
REDWOOD CITY, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible small molecules to treat and improve the live...
GlobeNewswire · 01/10 13:30
BRIEF-Biomea Fusion Releases Pre-Clinical Data With Bmf-219 In Diabetes
reuters.com · 01/06 14:18
Biomea Fusion Releases Pre-Clinical Data With BMF-219 In Diabetes
Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of irreversible small molecules to treat and improve the lives of patients
Benzinga · 01/06 13:35
Biomea Fusion Releases Pre-Clinical Data with BMF-219 in Diabetes
REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of irreversible small molecules to treat and improve the lives of p...
GlobeNewswire · 01/06 13:30
Biomea Fusion expands research facility
Biomea Fusion (BMEA +3.9%) announces the expansion of its research and development facility while it also moves into new headquarters in Redwood City, California.  The company says 18,000 sq. ft. R&D
Seekingalpha · 01/04 20:57
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BMEA. Analyze the recent business situations of Biomea Fusion, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BMEA stock price target is 22.60 with a high estimate of 27.00 and a low estimate of 13.00.
High27.00
Average22.60
Low13.00
Current 7.20
EPS
Actual
Estimate
-0.39-0.29-0.20-0.10
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 40
Institutional Holdings: 17.34M
% Owned: 59.70%
Shares Outstanding: 29.04M
TypeInstitutionsShares
Increased
16
1.81M
New
2
419
Decreased
9
644.19K
Sold Out
7
492.82K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.12%
Pharmaceuticals & Medical Research
-0.55%
Key Executives
President/Co-Founder/Chief Operating Officer/Director
Rainer Erdtmann
President/Co-Founder
Ramses Erdtmann
Chief Executive Officer/Co-Founder
Thomas Butler
Chief Financial Officer/Chief Accounting Officer
Franco Valle
Executive Vice President - Finance
Sunny Ryan
Executive Vice President
Thorsten Kirschberg
Chief Technology Officer
Heow Tan
Vice President - Operations
Naomi Cretcher
Independent Director
Eric Aguiar
Independent Director
Bihua Chen
Independent Director
Michael Hitchcock
Independent Director
John Kwon
Independent Director
Sumita Ray
Independent Director
Sotirios Stergiopoulos
No Data
About BMEA
Biomea Fusion, Inc. is a preclinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The Company has built FUSION System discovery platform to advance a pipeline of irreversible small molecule product candidates. The Company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The Company is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The Company is also advancing other preclinical irreversible programs for the treatment of select cancers.

Webull offers kinds of Biomea Fusion Inc stock information, including NASDAQ:BMEA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMEA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BMEA stock methods without spending real money on the virtual paper trading platform.